title: [Pregnancy, breast feeding and mood stabilisers: review and recommendations for practice].
abstract: BACKGROUND
  The high prevalence of bipolar affective disorder, the early age of onset and the even sex ratio imply that numerous women of childbearing age raise the question of mood stabilisers during pregnancy and breast feeding.
  
  
  RESULTS
  Some data suggest that giving appropriate answers to bipolar women who want to have children is an unmet need. We reviewed the risks and therapeutic options of this period of life in women with bipolar disorder. The generally accepted idea that pregnancy protects from relapses in bipolar disorders may be untrue and even deceitful. Lithium is the only mood stabiliser that can be prescribed in some cases during the first three months of pregnancy. DISCUSSION AND GUIDE LINES: We give explicit criteria that allow to consider this option: a severe illness prior to lithium prescription, a highly favourable outcome since initiation of lithium, no relapse during the last 18 months. When such conditions are satisfied, a reflection of the patient and at best of the couple must be proposed and associated with very complete information, both oral and written when possible, on the risks and benefits of the interruption and/or continuation of lithium. The teratogenic risks with anticonvulsants have been demonstrated and their prescription during the first three months of pregnancy should be avoided. Besides, there is some concern about the psycho-motor development of children born from women who were under anticonvulsants during pregnancy. The more recent mood stabilisers are not recommended either due to insufficient data. Breast feeding is not recommended under lithium, but seems safe under carbamazepine or valproate and its derivatives.
authors.affiliation: Clinique des Maladies Mentales et de l'Encéphale, Centre Hospitalier Sainte-Anne, Paris.
authors.forename: C
authors.initials: C
authors.lastname: Even
authors.forename: E S
authors.initials: ES
authors.lastname: Dorocant
authors.forename: J
authors.initials: J
authors.lastname: Thuile
authors.forename: M
authors.initials: M
authors.lastname: Kalck-stern
authors.forename: J D
authors.initials: JD
authors.lastname: Guelfi
mesh_terms: D000927:Anticonvulsants / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000188:drug therapy*; D001942:Breast Feeding; D005260:Female; D017408:Guidelines as Topic; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D016651:Lithium Carbonate / Q000009:adverse effects*; D009436:Neural Tube Defects / Q000139:chemically induced; D010818:Practice Patterns, Physicians'; D011247:Pregnancy; D012307:Risk Factors
chemical_list: D000927:Anticonvulsants; D014150:Antipsychotic Agents; D016651:Lithium Carbonate